• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Zolendrate (Reclast) Lowers Fracture Risk in Early Postmenopausal Women

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 17, 2025.

By Dennis Thompson HealthDay Reporter

FRIDAY, Jan. 17, 2025 -- Women past menopause can protect themselves from future fractures through infrequent, cheap IV infusions of a bone-strengthening drug.

Women 50 to 60 who got two IV infusions of zoledronate (Reclast) within five years had a 44% lower risk of spinal fractures, compared to women who received a placebo, according to results published Jan. 15 in the New England Journal of Medicine.

They also had a lower risk of major fractures related to osteoporosis and fragility fractures caused by little to no trauma, results show.

“The results show that prevention of vertebral fractures in early postmenopausal women is possible with very infrequent infusions of zoledronate,” concluded the research team led by Dr. Mark Bolland, an associate professor of medicine with the University of Auckland in New Zealand.

“The cost of the treatment, either to individual patients or to health systems, is likely to be low because the drug is generic and the frequency of administration low,” the team added.

At menopause, women have a 50% lifetime risk of suffering from a fracture, particularly as their bones grow thin and frail through the aging process, researchers said in background notes.

Zoledronate is used to treat or prevent osteoporosis caused by menopause, but it hadn’t been tested to see if early treatment could prevent bone loss in early postmenstrual women, even those with good bone density at the outset, researchers said.

For the study, researchers randomly assigned more than 1,000 women with an average age of 56 to receive either two IV infusions of zoledronate or a placebo.

The women received the infusions at the start of the study, and five years later. They were followed for a total of 10 years to see whether the drug protected their bone health.

Results showed that women who got zoledronate had a 40% lower risk of major fractures from osteoporosis compared to placebo, after 10 years of follow-up.

They also had a 28% lower risk of fragility fractures, which occur due to minimal trauma like a fall, and a 30% lower risk of any fracture.

“Early postmenopausal women who wish to reduce their risk of fracture could consider a strategy involving the administration of zoledronate either every 5 years or every 10 years,” the researchers wrote.

An editorial accompanying the study said that infrequent zoledronate infusions present “a real opportunity” to help many women avoid fractures.

The findings show that “primary prevention is possible in persons with any bone mineral density, in particular in women who have a sizeable risk of fracture in the foreseeable future and are concerned about this risk,” editorialist Dr. Roland Chapurlat, chief of rheumatology and bone diseases at Edouard Herriot Hospital in Lyon, France, wrote.

“In addition, infrequent doses of generic zoledronate, as used in this trial, will result in a low cumulative dose and minimize both the costs and the side effects of treatment,” Chapurlat concluded.

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted January 2025

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.